PARP inhibitors are drugs that inhibit PARP enzymes and constitute the only targeted therapies used in pancreatic cancer indicated for tumors with germline BRCA1/BRCA2 mutations [53]. Here, BRCA2 is linked to pancreatic neoplasm.